Market Place
Sourcing Support
Pasithea Gets FDA Fast Track for PAS-004 in NF1 Neurofibromas
01 Apr 2026 //
GLOBENEWSWIRE
Pasithea Therapeutics to Present at Oppenheimer HLS Conference
17 Feb 2026 //
GLOBENEWSWIRE
Pasithea Therapeutics Reveals PAS-004 Clinical Program Updates
13 Jan 2026 //
GLOBENEWSWIRE
Pasithea Therapeutics Closes $60M Public Stock Offering
02 Dec 2025 //
GLOBENEWSWIRE
Pasithea Therapeutics Prices $60M Public Stock Offering
28 Nov 2025 //
GLOBENEWSWIRE
Pasithea Therapeutics Receives $1M by ALS Association Grant
25 Nov 2025 //
GLOBENEWSWIRE
Pasithea Therapeutics Completes Cohort 7 Of PAS-004 Phase 1
24 Nov 2025 //
GLOBENEWSWIRE
Pasithea Therapeutics Reports Positive (PK) Data For PAS-004
21 Nov 2025 //
GLOBENEWSWIRE
Pasithea`s PAS-004 Shows Partial Response in Phase 1 Cancer Trial
20 Nov 2025 //
GLOBENEWSWIRE
Pasithea Therapeutics Activates South Korea Sites for PAS-004
16 Sep 2025 //
GLOBENEWSWIRE
Pasithea Enrolls Cohort 2 for PAS-004 Ph 1/1b Trial in Adult
08 Sep 2025 //
GLOBENEWSWIRE
Pasithea Therapeutics Reschedules H.C. Wainwright Conference
29 Aug 2025 //
GLOBENEWSWIRE
Pasithea to Present at HC Wainwright Annual Global Conference
28 Aug 2025 //
GLOBENEWSWIRE
Pasithea Completes Dosing for PAS-004 Ph1 NF1 Trial in Adults
31 Jul 2025 //
GLOBENEWSWIRE
Pasithea Therapeutics Appoints ETS2 Expert to Advisory Board
11 Jun 2025 //
GLOBENEWSWIRE
Pasithea Therapeutics: PAS-004 Inhibits ETS2 Signaling in IBD
20 May 2025 //
GLOBENEWSWIRE
Pasithea Starts PAS-004 NF1 Trial, Activates First Study Site
14 May 2025 //
GLOBENEWSWIRE
Pasithea Therapeutics Closes $5M Public Offering
07 May 2025 //
GLOBENEWSWIRE
Pasithea Therapeutics Reports Positive Results in Phase 1 Trial
06 May 2025 //
GLOBENEWSWIRE
Pasithea Therapeutics Prices $5M Public Offering
06 May 2025 //
GLOBENEWSWIRE
Pasithea Therapeutics Completes Enrollment & Dosing in Ph 1 Trail
29 Apr 2025 //
GLOBENEWSWIRE
Pasithea Therapeutics to Present Updated Data at 2025 ASCO Meeting
24 Apr 2025 //
GLOBENEWSWIRE
Pasithea Gets Positive SRC Recommendation for PAS-004 in Cancer
10 Apr 2025 //
GLOBENEWSWIRE
Pasithea Therapeutics to Present at 2025 NeauxCancer Conference
24 Mar 2025 //
GLOBENEWSWIRE
Pasithea Receives Positive SRC Recommendation for PAS-004 in Cancer
05 Feb 2025 //
GLOBENEWSWIRE
Pasithea Opens European Trial Sites, Doses Fourth Study Cohort
14 Jan 2025 //
GLOBENEWSWIRE
Pasithea Announces Positive SRC Recommendation For PAS-004
20 Nov 2024 //
GLOBENEWSWIRE
Pasithea Therapeutics Announces Positive Data From PAS-004 Trial
26 Sep 2024 //
GLOBENEWSWIRE
Pasithea Therapeutics Announces $5 Million Private Placement
26 Sep 2024 //
GLOBENEWSWIRE
Pasithea Completes PAS-004 Chronic Toxicity Studies
09 Sep 2024 //
GLOBENEWSWIRE
Pasithea Appoints Dr. Rebecca Brown to Scientific Advisory Board
03 Sep 2024 //
GLOBENEWSWIRE
Pasithea Therapeutics To Present At H.C. Wainwright Conference
28 Aug 2024 //
GLOBENEWSWIRE
